KatlamaC, GhosnJ, MurphyRL. Individualized antiretroviral therapeutic approaches: Less can be more. Aids, 2017; 31(8):1065–1071.
2.
LandmanR, De TruchisP, AssoumouL, et al.;ANRS 170 QUATUOR study group. A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial. Lancet HIV, 2022; 9(2):e79–e90.
3.
AmbrosioniJ, LeviL, AlagaratnamJ, et al;EACS Governing Board. Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023. HIV Med, 2023; 24(11):1126–1136.
TurkovaA, MooreCL, ButlerK, et al.;BREATHER (PENTA 16) trial Group. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial. De Socio GV, éditeur. PLoS One, 2018; 13(4):e0196239.
6.
CalinR, LandowskiS, ValantinM-A, et al.Efficacy of intermittent short cycles of integrase inhibitor-based maintenance ART in virologically suppressed HIV patients. J Antimicrob Chemother, 2020; 75(5):1321–1323.
7.
SellemB, AbdiB, LêM, et al.Intermittent bictegravir/emtricitabine/tenofovir alafenamide treatment maintains high level of viral suppression in virally suppressed people living with HIV. Jpm, 2023; 13(4):583.
